{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:41:48Z","timestamp":1794440508200,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Uppsala Monitoring Centre (UMC).","award":["CARTA\/2020\/354.707A"],"award-info":[{"award-number":["CARTA\/2020\/354.707A"]}]},{"name":"Uppsala Monitoring Centre (UMC).","award":["CARTA\/2020\/354.707A"],"award-info":[{"award-number":["CARTA\/2020\/354.707A"]}]},{"name":"Uppsala Monitoring Centre (UMC).","award":["CARTA\/2020\/354.707A"],"award-info":[{"award-number":["CARTA\/2020\/354.707A"]}]},{"name":"Uppsala Monitoring Centre (UMC).","award":["CARTA\/2020\/354.707A"],"award-info":[{"award-number":["CARTA\/2020\/354.707A"]}]},{"name":"Uppsala Monitoring Centre (UMC).","award":["CARTA\/2020\/354.707A"],"award-info":[{"award-number":["CARTA\/2020\/354.707A"]}]},{"name":"Uppsala Monitoring Centre (UMC).","award":["CARTA\/2020\/354.707A"],"award-info":[{"award-number":["CARTA\/2020\/354.707A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The World Health Organization recommends dolutegravir (DTG) as the for first-line and second-line antiretroviral therapy (ART) worldwide. However, little is known about the acceptability and tolerability of DTG-based ART at routine points-of-care in Uganda. We set out to explore the perceptions of clinicians in ART clinics regarding the acceptability and tolerability of DTG-based ART since national roll-out in March 2018 in Uganda.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We adopted a qualitative exploratory design involving 49 participants. Between September 2020 and February 2021, we conducted 22 in-depth interviews with clinicians in the ART clinics of 12 purposively selected health facilities across Uganda. The selection of study sites ensured diversity in facility ownership-type (public\/private), level of service delivery (tertiary\/secondary\/primary) and the four major geographic sub-regions of Uganda. We conducted three focus group discussions with 27 clinicians in the participating facilities. Data were analyzed by thematic approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Clinicians in ART clinics acknowledged that DTG-based ART is well tolerated by the majority of their patients who appreciate the reduced pill burden, perceived less side effects and superior viral load suppression. However, they reported that a number of their patients experience adverse drug reactions (ADRs) after being transitioned to DTG. Hyperglycemia is, by far, the most commonly reported suspected ADR associated with DTG-based regimens and was cited in all but two participating facilities. Insomnia, weight gain and reduced libido are among the other frequently cited suspected ADRs. In addition, clinicians in ART clinics perceived some of the suspected ADRs as resulting from drug interactions between dolutegravir and isoniazid. Weak diagnostic capacities and shortage of associated commodities (e.g. glucometers and test kits) were reported as impediments to understanding the full extent of ADRs associated DTG-based ART.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While DTG-based regimens were perceived by clinicians in ART clinics to be well tolerated by the majority of their patients, they also reported that a number of patients experience suspected ADRs key among which were hyperglycemia, insomnia and reduced libido. Based on the perspectives of clinicians, we recommend that future studies examine the prevalence of dolutegravir-induced hyperglycemia in patients in Uganda.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-021-06933-8","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:02:42Z","timestamp":1638871362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study"],"prefix":"10.1186","volume":"21","author":[{"given":"Henry","family":"Zakumumpa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy Eric","family":"Kitutu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Byomire","family":"Ndagije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakitto-Kesi","family":"Diana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquellyn Nambi","family":"Ssanyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kiguba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"issue":"10144","key":"6933_CR1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(18)31070-5","volume":"392","author":"LG Bekker","year":"2018","unstructured":"Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society\u2014Lancet Commission. Lancet. 2018;392(10144):312\u201358.","journal-title":"Lancet"},{"key":"6933_CR2","unstructured":"WHO. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir\/lamivudine\/dolutegravir (TLD) Retrieved 1 Jun 2021. https:\/\/www.who.int\/hiv\/pub\/arv\/DTG-TLD-arv_briefing_2018.pdf."},{"issue":"2","key":"6933_CR3","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","volume":"6","author":"AN Phillips","year":"2019","unstructured":"Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV. 2019;6(2):e116\u201327.","journal-title":"Lancet HIV"},{"issue":"2","key":"6933_CR4","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/S2352-3018(18)30331-X","volume":"6","author":"J Dorward","year":"2019","unstructured":"Dorward J, Hamers RL. Dolutegravir in sub-Saharan Africa: context is crucial. Lancet HIV. 2019;6(2):e72\u20133.","journal-title":"Lancet HIV"},{"issue":"3","key":"6933_CR5","doi-asserted-by":"crossref","first-page":"e25085","DOI":"10.1002\/jia2.25085","volume":"21","author":"A Zheng","year":"2018","unstructured":"Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, Walensky RP, Freedberg KA. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. J Int AIDS Soc. 2018;21(3):e25085.","journal-title":"J Int AIDS Soc."},{"issue":"1","key":"6933_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-017-2009-6","volume":"17","author":"H Zakumumpa","year":"2017","unstructured":"Zakumumpa H, Bennett S, Ssengooba F. Alternative financing mechanisms for ART programs in health facilities in Uganda: a mixed-methods approach. BMC Health Serv Res. 2017;17(1):1\u20131.","journal-title":"BMC Health Serv Res"},{"key":"6933_CR7","unstructured":"Uganda PEPFAR Country Operational Plan (COP) 2017. Retrieved 4 Nov 2019. https:\/\/www.state.gov\/wp-content\/uploads\/2019\/08\/Uganda-18.pdf"},{"key":"6933_CR8","unstructured":"URC. Uganda launces 100-day plan to prevent TB among people living with HIV. https:\/\/www.urc-chs.com\/news\/uganda-launches-100-day-plan-prevent-tb-among-people-living-hiv. Accessed 20 Feb 2020."},{"key":"6933_CR9","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/01.aids.0000391023.03037.1f","volume":"24","author":"H Getahun","year":"2010","unstructured":"Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24:S57-65.","journal-title":"AIDS"},{"key":"6933_CR10","unstructured":"National Drug Authority. National Pharmacovigilance Bulletin 2018. Retrieved 4 Feb 2020. https:\/\/www.nda.or.ug\/nda\/files\/downloads\/NDA-PVB-ISSUE-3-%20FEB-2018-WEB(3).pdf."},{"key":"6933_CR11","unstructured":"Daily Monitor. People with HIV report side effects from new drug. Retrieved 9 Dec 2019. https:\/\/www.monitor.co.ug\/News\/National\/People-with-HIV-report-side-effects-from-new-drug\/688334-5345492-37f8xw\/index.html."},{"issue":"7","key":"6933_CR12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","volume":"70","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, Koethe JR, Sterling TR. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020;70(7):1267\u201374.","journal-title":"Clin Infect Dis"},{"issue":"10213","key":"6933_CR13","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/S0140-6736(19)32638-8","volume":"394","author":"AD Lyerly","year":"2019","unstructured":"Lyerly AD. Dolutegravir: advancing ethical research in pregnancy. Lancet. 2019;394(10213):1972\u20134.","journal-title":"Lancet"},{"issue":"1","key":"6933_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-020-09991-w","volume":"20","author":"Y Alhassan","year":"2020","unstructured":"Alhassan Y, Twimukye A, Malaba T, Orrell C, Myer L, Waitt C, Lamorde M, Kambugu A, Reynolds H, Khoo S, Taegtmeyer M. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda. BMC Public Health. 2020;20(1):1\u20132.","journal-title":"BMC Public Health"},{"key":"6933_CR15","doi-asserted-by":"crossref","unstructured":"Villa G, Garcia D, Fray D, Clarke A, Ackley C. Protocol for a qualitative study exploring the experiences and perceptions of dolutegravir\/lamivudine dual antiretroviral therapy (the PEDAL Study) in people living with HIV. medRxiv. 2021.","DOI":"10.1101\/2021.08.13.21262001"},{"issue":"1","key":"6933_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-020-05580-0","volume":"20","author":"Y Alhassan","year":"2020","unstructured":"Alhassan Y, Twimukye A, Malaba T, Orrell C, Myer L, Waitt C, Lamorde M, Kambugu A, Reynolds H, Khoo S, Taegtmeyer M. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda. BMC Health Serv Res. 2020;20(1):1\u20132.","journal-title":"BMC Health Serv Res"},{"key":"6933_CR17","unstructured":"AmaraSingham LR. Social and cultural perspectives on medication refusal. Am J Psychiatry. 1980."},{"key":"6933_CR18","doi-asserted-by":"publisher","DOI":"10.3201\/eid2203.151430","author":"J Furin","year":"2016","unstructured":"Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S. Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis. Emerg Infect Dis. 2016. https:\/\/doi.org\/10.3201\/eid2203.151430.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"6933_CR19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1089\/jwh.2012.3972","volume":"23","author":"M Manteuffel","year":"2014","unstructured":"Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health. 2014;23(2):112\u20139.","journal-title":"J Womens Health"},{"issue":"32","key":"6933_CR20","doi-asserted-by":"crossref","first-page":"e16721","DOI":"10.1097\/MD.0000000000016721","volume":"98","author":"TT Brehm","year":"2019","unstructured":"Brehm TT, Franz M, H\u00fcfner A, Hertling S, Schmiedel S, Degen O, Kreuels B, Wiesch ZJS. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naive and-experienced patients. Medicine. 2019;98(32):e16721.","journal-title":"Medicine"},{"issue":"13","key":"6933_CR21","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","volume":"31","author":"L Elzi","year":"2017","unstructured":"Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P, G\u00fcnthard H, Bernasconi E, Battegay M. Adverse events of raltegravir and dolutegravir. AIDS (London, England). 2017;31(13):1853.","journal-title":"AIDS (London, England)"},{"issue":"7","key":"6933_CR22","doi-asserted-by":"crossref","first-page":"e25352","DOI":"10.1002\/jia2.25352","volume":"22","author":"LM Mofenson","year":"2019","unstructured":"Mofenson LM, Pozniak AL, Wambui J, Raizes E, Ciaranello A, Clayden P, Ehrenkranz P, Fakoya A, Hill A, Khoo S, Mahaka I. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. J Int AIDS Soc. 2019;22(7):e25352.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"6933_CR23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/nhs.12048","volume":"15","author":"M Vaismoradi","year":"2013","unstructured":"Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398\u2013405.","journal-title":"Nurs Health Sci"},{"issue":"11","key":"6933_CR24","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40264-020-00974-9","volume":"43","author":"EA Laker","year":"2020","unstructured":"Laker EA, Arinaitwe A, Owarwo N, Onzia A, Nasasira B, Wailagala A, Kalule I, Anguzu G, Kiragga A, Seden K, Lwanga I. The potential teratogenicity alert for women conceiving on dolutegravir-based regimens: an assessment of risk communication by an urban HIV clinic in Uganda and choices made by women. Drug Saf. 2020;43(11):1133\u201340.","journal-title":"Drug Saf"},{"issue":"7","key":"6933_CR25","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2352-3018(20)30042-4","volume":"7","author":"M Lamorde","year":"2020","unstructured":"Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, Kiragga A, Lwanga IB, Castelnuovo B. Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV. 2020;7(7):e461\u20132.","journal-title":"Lancet HIV"},{"issue":"1","key":"6933_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):1\u20133.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"6933_CR27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/160940690600500107","volume":"5","author":"J Fereday","year":"2006","unstructured":"Fereday J, Muir-Cochrane E. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Int J Qual Methods. 2006;5(1):80\u201392.","journal-title":"Int J Qual Methods"},{"key":"6933_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15016","author":"V Stanulovi\u0107","year":"2021","unstructured":"Stanulovi\u0107 V, Hodolic M, Mitsikostas DD, Papadopoulos D. Drug tolerability: how much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies. Br J Clin Pharmacol. 2021. https:\/\/doi.org\/10.1111\/bcp.15016.","journal-title":"Br J Clin Pharmacol"},{"key":"6933_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12960-020-00479-7","volume":"18","author":"H Zakumumpa","year":"2020","unstructured":"Zakumumpa H. Reimagining the role of the nursing workforce in Uganda after more than a decade of ART scale-up. Hum Resour Health. 2020;18:1\u20139.","journal-title":"Hum Resour Health"},{"issue":"1","key":"6933_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12960-016-0160-5","volume":"14","author":"H Zakumumpa","year":"2016","unstructured":"Zakumumpa H, Taiwo MO, Muganzi A, Ssengooba F. Human resources for health strategies adopted by providers in resource-limited settings to sustain long-term delivery of ART: a mixed-methods study from Uganda. Hum Resour Health. 2016;14(1):1\u20131.","journal-title":"Hum Resour Health"},{"issue":"4","key":"6933_CR31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1037\/1089-2699.2.4.253","volume":"2","author":"DW Seal","year":"1998","unstructured":"Seal DW, Bogart LM, Ehrhardt AA. Small group dynamics: The utility of focus group discussions as a research method. Group Dyn Theory Res Pract. 1998;2(4):253.","journal-title":"Group Dyn Theory Res Pract"},{"issue":"1","key":"6933_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-020-5069-y","volume":"20","author":"H Zakumumpa","year":"2020","unstructured":"Zakumumpa H, Rujumba J, Kwiringira J, Katureebe C, Spicer N. Understanding implementation barriers in the national scale-up of differentiated ART delivery in Uganda. BMC Health Serv Res. 2020;20(1):1\u20136.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"6933_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-020-05996-8","volume":"21","author":"H Zakumumpa","year":"2021","unstructured":"Zakumumpa H, Paina L, Wilhelm J, Ssengooba F, Ssegujja E, Mukuru M, Bennett S. The impact of loss of PEPFAR support on HIV services at health facilities in low-burden districts in Uganda. BMC Health Serv Res. 2021;21(1):1\u20132.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"6933_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-018-3500-4","volume":"18","author":"H Zakumumpa","year":"2018","unstructured":"Zakumumpa H, Rujumba J, Kwiringira J, Kiplagat J, Namulema E, Muganzi A. Understanding the persistence of vertical (stand-alone) HIV clinics in the health system in Uganda: a qualitative synthesis of patient and provider perspectives. BMC Health Serv Res. 2018;18(1):1\u20133.","journal-title":"BMC Health Serv Res"},{"key":"6933_CR35","unstructured":"Gilson L, World Health Organization. Health policy and system research: a methodology reader: the abridged version. World Health Organization; 2013."},{"issue":"1","key":"6933_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-13-1","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13(1):1\u20138.","journal-title":"BMC Med Res Methodol"},{"key":"6933_CR37","doi-asserted-by":"crossref","unstructured":"Jansz J. Masculine identity and restrictive emotionality. Gender and emotion: social psychological perspectives. 2000; 166\u201386","DOI":"10.1017\/CBO9780511628191.009"},{"issue":"1","key":"6933_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-019-7652-x","volume":"19","author":"M Kagujje","year":"2019","unstructured":"Kagujje M, Mubiana ML, Mwamba E, Muyoyeta M. Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons. BMC Public Health. 2019;19(1):1\u20134.","journal-title":"BMC Public Health"},{"issue":"1","key":"6933_CR39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jac\/dkx365","volume":"73","author":"M McLaughlin","year":"2018","unstructured":"McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother. 2018;73(1):258\u201360.","journal-title":"J Antimicrob Chemother"},{"key":"6933_CR40","unstructured":"Odenyo JA. Prevalence of Dolutegravir Associated Hyperglycemia and Its Covariates Among Persons Living With HIV on Treatment at Kenyatta National Hospital (Doctoral dissertation, University of Nairobi). Retrieved 1 Jun 2021. http:\/\/erepository.uonbi.ac.ke\/handle\/11295\/154331."},{"key":"6933_CR41","unstructured":"Lo J, Oyee J, Crawford M, Grove R, DeMasi R, Curtis L, Fettiplace A, Vannappagari V, Payvandi N, Aboud M, van Wyk J. Dolutegravir and insulin resistance. CROI. 2019"},{"issue":"1","key":"6933_CR42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/09540121.2017.1344350","volume":"30","author":"V Haldane","year":"2018","unstructured":"Haldane V, Legido-Quigley H, Chuah FL, Sigfrid L, Murphy G, Ong SE, Cervero-Liceras F, Watt N, Balabanova D, Hogarth S, Maimaris W. Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review. AIDS Care. 2018;30(1):103\u201315.","journal-title":"AIDS Care"},{"issue":"8","key":"6933_CR43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/tmi.12901","volume":"22","author":"M Duffy","year":"2017","unstructured":"Duffy M, Ojikutu B, Andrian S, Sohng E, Minior T, Hirschhorn LR. Non-communicable diseases and HIV care and treatment: models of integrated service delivery. Trop Med Int Health. 2017;22(8):926\u201337.","journal-title":"Trop Med Int Health"},{"issue":"5","key":"6933_CR44","doi-asserted-by":"crossref","first-page":"e0232419","DOI":"10.1371\/journal.pone.0232419","volume":"15","author":"VM Nabitaka","year":"2020","unstructured":"Nabitaka VM, Nawaggi P, Campbell J, Conroy J, Harwell J, Magambo K, Middlecote C, Caldwell B, Katureebe C, Namuwenge N, Atugonza R. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: a mixed-methods prospective cohort study. PLoS ONE. 2020;15(5):e0232419.","journal-title":"PLoS ONE"},{"issue":"5","key":"6933_CR45","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1111\/hiv.12540","volume":"19","author":"AF Capetti","year":"2018","unstructured":"Capetti AF, Di Giambenedetto S, Latini A, Sterrantino G, De Benedetto I, Cossu MV, Gori A. Morning dosing for dolutegravir-related insomnia and sleep disorders. HIV Med. 2018;19(5):e62\u20133.","journal-title":"HIV Med"},{"issue":"1","key":"6933_CR46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciy426","volume":"68","author":"ER Elliot","year":"2019","unstructured":"Elliot ER, Wang X, Singh S, Simmons B, Vera JH, Miller RF, Fitzpatrick C, Moyle G, McClure M, Boffito M. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019;68(1):87\u201395.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"6933_CR47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","volume":"21","author":"C Hoffmann","year":"2019","unstructured":"Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21(1):4\u201310.","journal-title":"AIDS Rev"},{"issue":"2","key":"6933_CR48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00002018-200022020-00007","volume":"22","author":"H Dormann","year":"2000","unstructured":"Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, Hahn EG, Levy M, Brune K, Geisslinger G. Incidence and costs of adverse drug reactions during hospitalisation. Drug Saf. 2000;22(2):161\u20138.","journal-title":"Drug Saf"},{"issue":"5","key":"6933_CR49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/apc.2006.20.359","volume":"20","author":"LS Rintamaki","year":"2006","unstructured":"Rintamaki LS, Davis TC, Skripkauskas S, Bennett CL, Wolf MS. Social stigma concerns and HIV medication adherence. AIDS Patient Care STDS. 2006;20(5):359\u201368.","journal-title":"AIDS Patient Care STDS"},{"key":"6933_CR50","doi-asserted-by":"crossref","first-page":"18640","DOI":"10.7448\/IAS.16.3.18640","volume":"16","author":"IT Katz","year":"2013","unstructured":"Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, Tsai AC. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16:18640.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"6933_CR51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.pec.2011.02.007","volume":"83","author":"SJ Shoemaker","year":"2011","unstructured":"Shoemaker SJ, de Oliveira DR, Alves M, Ekstrand M. The medication experience: preliminary evidence of its value for patient education and counseling on chronic medications. Patient Educ Couns. 2011;83(3):443\u201350.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"6933_CR52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10461-019-02644-z","volume":"24","author":"G Camacho","year":"2020","unstructured":"Camacho G, Kalichman S, Katner H. Anticipated HIV-related stigma and HIV treatment adherence: the indirect effect of medication concerns. AIDS Behav. 2020;24(1):185\u201391.","journal-title":"AIDS Behav"},{"issue":"1","key":"6933_CR53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/heapol\/czaa166","volume":"36","author":"J Parkhurst","year":"2021","unstructured":"Parkhurst J, Ghilardi L, Webster J, Snow RW, Lynch CA. Competing interests, clashing ideas and institutionalizing influence: insights into the political economy of malaria control from seven African countries. Health Policy Plan. 2021;36(1):35\u201344.","journal-title":"Health Policy Plan"},{"issue":"12","key":"6933_CR54","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/tmi.12609","volume":"20","author":"J van Griensven","year":"2015","unstructured":"van Griensven J, Choun K, Chim B, Thai S, Lorent N, Lynen L. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. Trop Med Int Health. 2015;20(12):1823\u201331.","journal-title":"Trop Med Int Health"},{"issue":"1","key":"6933_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12992-018-0431-0","volume":"14","author":"HH Ampadu","year":"2018","unstructured":"Ampadu HH, Hoekman J, Arhinful D, Amoama-Dapaah M, Leufkens HG, Dodoo AN. Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences. Glob Health. 2018;14(1):1\u20137.","journal-title":"Glob Health"},{"issue":"8","key":"6933_CR56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/135965350701200808","volume":"12","author":"O Keiser","year":"2007","unstructured":"Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, Bernasconi E, Vernazza PL, Rickenbach M, Telenti A, Furrer H. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir Ther. 2007;12(8):1157.","journal-title":"Antivir Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06933-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T14:16:11Z","timestamp":1673964971000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06933-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6933"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06933-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by Mildmay Uganda Research Ethics Committee(MUREC) under instrument: REC REF 0712-2020. MUREC is accredited by the Uganda National Council for Science and Technology (UNCST). All participants signed a written informed consent form before participating in the study. Data were collected in accordance with international conventions and guidelines on research involving human subjects such as the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1222"}}